crizotinib
ALK Inhibitors Show Benefit in Subset of GI Cancers, Strengthening Tissue-Agnostic Potential
Premium
Researchers urged other oncologists to look for ALK rearrangements in GI patients and try to get them on ALK inhibitors through trials or compassionate use programs.
Pfizer's Oncology Business Grows Sales 4 Percent in Q1
The firm's targeted therapies Ibrance and Xalkori saw a drop in sales, while its second-generation ALK inhibitor Lorbrena saw a double-digit revenue increase.
Xcovery's Ensartinib Approved for First-Line ALK-Positive NSCLC in China
The drug was previously approved in the country as a second-line treatment for ALK-positive non-small cell lung cancer patients.
In Brief This Week: Ideaya Biosciences, Pfizer, Strata Oncology, Qualigen Therapeutics
News items for the week of March 14, 2022.
Pfizer Q4 Oncology Revenues Grow Seven Percent Despite Ibrance, Xalkori Slowdowns
Pfizer's second-generation ALK inhibitor Lorbrena, BRAF inhibitor Braftovi, and MEK inhibitor Mektovi saw increased sales in the fourth quarter.